Home / Market News / $ARDX

$ARDX news and market catalysts

The 8 most recent market catalysts affecting $ARDX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 2 high impact 1 bullish 5 bearish Biotechnology
Nov 18, 2026 Corporate Catalyst Neutral Impact 55
Ardelyx, Inc. Receives Schedule 13G Filing
Tang Capital Management LLC filed a Schedule 13G on November 17, 2026, disclosing beneficial ownership of over 5% of Ardelyx, Inc.'s voting stock. This filing indicates that a sign…
Nov 4, 2026 Corporate Catalyst Neutral Impact 75
Ardelyx Reports Third Quarter 2026 Financial Results
Ardelyx announced its third-quarter 2026 financial results, reporting a 19% year-over-year increase in product revenue to $125.5 million. The company also reiterated its full-year …
Nov 3, 2026 Corporate Catalyst Bullish Impact 65
Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial for IBSRELA in Chronic Idiopathic Constipation
Ardelyx announced the completion of enrollment for its Phase 3 ACCEL clinical trial for IBSRELA in chronic idiopathic constipation (CIC), ahead of schedule. This is a positive oper…
Aug 10, 2026 Corporate Catalyst Bearish Impact 55
Citigroup Maintains Buy on Ardelyx, Lowers Price Target to $11
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on Ardelyx (ARDX) but lowered the price target from $14 to $11. This action suggests that while the analyst still sees…
Aug 7, 2026 Corporate Catalyst Bearish Impact 75
Ardelyx shares are trading lower after BTIG lowered its price target on the stock from $17 to $14.
The BTIG price target downgrade from $17 to $14 for Ardelyx (ARDX) is a significant negative catalyst for the stock. Such a substantial reduction from a prominent analyst firm ofte…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
BTIG Maintains Buy on Ardelyx, Lowers Price Target to $14
BTIG analyst Julian Harrison maintained a 'Buy' rating on Ardelyx, signaling continued confidence in the company's long-term prospects. However, the price target was lowered from $…
Aug 6, 2026 Corporate Catalyst Bearish Impact 85
Ardelyx shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline represents a direct corporate catalyst, as Ardelyx's stock is reacting immediately and negatively to its own financial performance. The 'worse-than-expected' nature o…
Aug 6, 2026 Corporate Catalyst Bearish Impact 92
Ardelyx Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $118.100M Miss $121.601M Estimate
Ardelyx (ARDX) announced its Q2 financial results, reporting a loss of $(0.07) per share, significantly missing the analyst consensus of $(0.05) by 40%. Additionally, quarterly sal…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.